ASND Stock: Price, Earnings History and SEC Filings
Ascendis Pharma A/S (ASND) last traded at $251.27, down 0.68% on the latest session and up 10.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $3.29 against an analyst estimate of $0.78, a beat of 321.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ASND earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $3.29 | $0.78 | +321.79% |
| Mar 2026 | May 7, 2026 | $0.32 | $0.21 | +52.38% |
| Dec 2025 | Feb 11, 2026 | $-0.64 | $-0.06 | -966.67% |
| Sep 2025 | Nov 12, 2025 | $-1.17 | $-0.41 | -185.37% |
ASND beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ASND
Insider filing activity
ASND insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ASND news
- TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 YearsOct 26, 2026 · finance.yahoo.com
- Bet on This New GLP-1 ETF to Gain Exposure to a Booming MarketOct 21, 2026 · finance.yahoo.com
- RBC Capital names top healthcare stocks as sector upgraded to overweightOct 20, 2026 · finance.yahoo.com
About Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Denmark. Its fiscal year ends in December.